The Role of Biologics in the Treatment of Food Allergy
The Journal of Allergy and Clinical Immunology: In Practice · 2024-03 · 12 (3) · 562-568
DOI: 10.1016/j.jaip.2023.11.032 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Allergy and Clinical Immunology: In Practice, 2024-03. Verfasst von Sayantani B Sindher und 5 weiteren Autor:innen. Beteiligte Einrichtung: Sean N. Parker Center for Allergy and Asthma Research at Stanford University, Stanford, Calif. Hauptthemen laut MEDLINE: Food Hypersensitivity, Biological Products. Die Arbeit wurde bisher 36-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAID NIH HHS, National Institute of Allergy and Infectious Diseases.
Abstract (Originalsprache)
The landscape of food allergy (FA) treatment is poised for a paradigm shift with the emergence of biologic therapies. The Food and Drug Administration approval of a standardized peanut powder for oral immunotherapy in 2020 marked a milestone, signaling a departure from allergen avoidance toward proactive treatment strategies. Although oral immunotherapy has been proven effective in desensitizing patients to specific allergens, there are several limitations such as lacking standardization, a long-time commitment to achieve maintenance, and adverse events. Biologics, including omalizumab, dupilumab, and antialarmins, have shown promise in treating various allergic diseases, including FA. These biologics target the underlying immunologic pathways driving allergic reactions, offering an antigen-agnostic approach. Omalizumab (anti-IgE) has been the most studied biologic in this space and can be used both as an adjunct therapy with oral immunotherapy and as monotherapy. Dupilumab targeting IL-4 and IL-13 also shows promise as an adjunct therapy. The emergence of antialarmins further broadens the spectrum of FA treatment possibilities. Biologics represent a transformative approach to FA treatment, directly addressing the underlying mechanisms. Future research should focus on patient selection criteria, personalized biomarker panels, optimal timing of intervention, and treatment durations.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Sean N. Parker Center for Allergy and Asthma Research at Stanford University, Stanford, Calif.
- Allergy Unit - Bambino Gesù Children's Hospital, Rome, Italy.
- Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Allergology and Immunology, Berlin, Germany; Institute of Allergology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität B…
- Department of Pediatrics, Johns Hopkins University School of Medicine, Baltimore, Md.
- Sean N. Parker Center for Allergy and Asthma Research at Stanford University, Stanford, Calif. Electronic address: schinths@stanford.edu.
Förderung
- NIAID NIH HHS
- National Institute of Allergy and Infectious Diseases
Zitieren
APA
Sindher, S. B., Fiocchi, A., Zuberbier, T., Arasi, S., Wood, R. A., & Chinthrajah, R. S. (2024). The Role of Biologics in the Treatment of Food Allergy. The Journal of Allergy and Clinical Immunology: In Practice, 12(3), 562-568. https://doi.org/10.1016/j.jaip.2023.11.032
Vancouver
Sindher SB, Fiocchi A, Zuberbier T, Arasi S, Wood RA, Chinthrajah RS. The Role of Biologics in the Treatment of Food Allergy. The Journal of Allergy and Clinical Immunology: In Practice. 2024;12(3):562-568. doi:10.1016/j.jaip.2023.11.032
BibTeX
@article{Sindher2024,
author = {Sindher, Sayantani B and Fiocchi, Alessandro and Zuberbier, Torsten and Arasi, Stefania and Wood, Robert A and Chinthrajah, R Sharon},
title = {The Role of Biologics in the Treatment of Food Allergy},
journal = {The Journal of Allergy and Clinical Immunology: In Practice},
year = {2024},
volume = {12},
number = {3},
pages = {562--568},
doi = {10.1016/j.jaip.2023.11.032}
}
EUVIMED